Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

BMC Cancer

Table 1 Baseline characteristics, clinical course and mechanism of acquired resistance to EGFR-TKI in 26 patients

SN	Sex	Age	Histology	EGFR mutation	Changes in 2^ndBx	TKI	PFS (months)	OS (months)	Bx site
SN	Sex	Age	Histology		Changes in 2^ndBx	TKI			1st	2nd
1	M	80	ACC	19 del	T790M + H1047L (PIK3CA)	Gefitinib	34.7	65.7	RUL	RUL
2	F	40	ACC	19 del	T790M	Gefitinib	12.7	17.1	LLL	LN
3	F	48	ACC	L858R	T790M + AXL	Gefitinib	11.5	38.9	LLL	RLL
4	F	64	SqCC	19 del	T790M + MET amp	Gefitinib	7.8	14.2	RUL	RUL
5	F	73	ACC	L858R	T790M + MET amp	Gefitinib	13.1	47.7	RLL	RLL
6	M	67	ACC	L858R	T790M	Gefitinib	16.7	29.1	RUL	Liver
7	M	53	ACC	19 del	T790M	Gefitinib	15.8	79.4	LUL	LUL
8	F	48	ACC	19 del	T790M	Gefitinib	18.9	50.9	LN	LN
9	F	57	ACC	19 del	T790M	Gefitinib	16.2	37.2	LLL	Effusion
10	M	56	ACC	19 del	T790M	Gefitinib	14.8	28.9	RUL	RUL
11	F	54	ACC	19 del	T790M	Gefitinib	28.7	58.2	RML	LN
12	M	49	ACC	L858R	WT EGFR	Gefitinib	6.6	89.2	RUL	Liver
13	F	50	ACC	19 del	MET amp	Gefitinib	10.7	35.2	LN	LUL
14	F	64	ACC	L858R	AXL	Gefitinib	25.4	94.6	LUL	RUL
15	M	67	ACC	19 del	AXL	Gefitinib	11.4	30.2	LUL	Bone
16	M	59	ACC	19 del	AXL	Gefitinib	4.3	41.3	RLL	LN
17	F	76	ACC	19 del	AXL	Gefitinib	10.7	31.0	RUL	RUL
18	F	72	ACC	19 del	None	Gefitinib	26.1	46.4	RML	RML
19	F	51	ACC	L858R	None	Gefitinib	6.1	23.0	Bone	LN
20	M	63	ACC	L858R	None	Gefitinib	5.0	9.6	RLL	RLL
21	F	73	ACC	L858R	None	Gefitinib	3.9	25.1	LN	LN
22	F	66	ACC	L858R	None	Gefitinib	4.8	21.2	LUL	LUL
23	F	57	ACC	19 del	None	Gefitinib	11.0	36.2	LUL	LUL
24	M	65	ACC	L858R	None	Gefitinib	5.4	20.6	RLL	RLL
25	F	56	ACC	19 del	CD56↑	Gefitinib	8.7	32.3	RUL	RUL
26	M	50	ACC	19 del	CD56↑	Gefitinib	5.9	15.4	LUL	LUL

ACC, Adenocarcinoma; SqCC, Squamous cell carcinoma; TKI, Tyrosine kinase inhibitor; PFS, Progression-free survival; OS, Overall survival; Bx, Biopsy; RUL, Right upper lobe; RML, Right middle lobe; RLL, Right lower lobe; LUL, Left upper lobe; LLL, Left lower lobe; LN, Lymph node; WT, Wild-type; ↑, increased expression.

ISSN: 1471-2407